

# BioServices 2011

## Presentations at the BioServices Forum

Tuesday, 11 October 2011

### BioDrug Discovery: 10:00 – 11:30 Uhr/hrs

10:00 - 10:15	<b>Drugabilis</b>	Pharmaceutical drugability for research	Isabelle Menier (Chief Operating Officer)
10:15 - 10:30	<b>Plant Advanced Technologies</b>	Innovative recombinant proteins and active compounds from plants	Jean-Paul Fevre (President)
10:30 - 10:45	<b>Qlucore</b>	Live demonstration of the latest bioinformatics tool for instant exploration of large datasets	Ann Holmberg (Director Sales)
10:45 – 11:00	<b>ProQinase</b>	ProQinase - Your solution provider for drug discovery in oncology	Sebastian Dempe, PhD (Business Development Manager)
11:00 – 11:15	<b>Aros Applied Biotechnology</b>	Genomic outsourcing: From extraction of nucleic acids to data analysis	Mr. Brian Sørensen (CEO)
11:15 – 11:30	<b>Pharmacelsus</b>	CYP450 induction studies - HepaRG® cells as an alternative tool to human primary hepatocytes	Dr. Julia Frühwald (Project Coordinator Research & Development)

### BioDrug Diagnostics/Analytics: 11:30 – 13:00 Uhr/hrs

11:30 – 11:45	<b>Forschungszentrum für Medizintechnik und Biotechnologie</b>	Bioaffinity tools for the detection and purification of bio molecules	Dr. Peter Miethe (Geschäftsführer)
11:45 – 12:00	<b>IMGM Laboratories</b>	IMGM – your partner for genomic services	Dr. Jennifer K. Kuhn (Sales Representative)
12:00 – 12:15	<b>Bioanalytik-Muenster</b>	Characterisation of nanomaterials in biological systems	Dr. Klaus-M. Weltring (Managing Director)
12:15 – 12:30	<b>HISTALIM</b>	Innovative solutions in histology through immunolabelings and image processing	Laurence Sifre (Project Manager Biotechnologies)

<b>12:30 – 12:45</b>	<b>Abberior GmbH</b>	Novel fluorescence markers optimized for nanoscopy in biological applications	Dr. Gerald Donnert, (Managing Director)
<b>12:45 – 13:00</b>	<b>ADA InVivo B.V.</b>	The next step in managing immunogenicity and hypersensitivity of protein drugs at an early stage: in vivo testing by usage of dedicated animal models	Melody Sauerborn, PhD (CEO)

**Pause/ lunch break: 13:00 bis 14:00**

**BioDrug Manufacturing: 14:00 – 15:00 Uhr/hrs**

<b>14:00 – 14:15</b>	<b>DSM Biologics B.V.</b>	Technologies lead to shorter process time & cost advantages - A case study by DSM Biologics	Dr. Fritjof Linz (Senior Director, New Business Development & Marketing)
<b>14:15 – 14:30</b>	<b>DBI</b>	DBI - CMO for sterile forms	Marion Pocaly (Business Development Manager)
<b>14:30 – 14:45</b>	<b>RD Biotech (France)</b>	In vitro mab bioproduction service for preclinical applications	Philippe Dulieu (President & CSO)
<b>14:45 – 15:00</b>	<b>Synthelis</b>	Effective solutions for membrane protein expression	Bruno Tillier (CEO)

**BioDrug Development: 15:00 – 15:45 Uhr/hrs\***

<b>15:00 – 15:15</b>	<b>Pharmatest Services</b>	Avoiding pitfalls of drug development	Heikki Vuoriskoski (VP, Business Development)
<b>15:15 – 15:30</b>	<b>Cytocentrics</b>	Preclinical drug safety: high quality data obtained with a new automated patch clamp platform	Dr. Andrea van Bergen (Business Development Manager)